Literature DB >> 8709197

Epitopes exposed on hepatitis delta virus ribonucleoproteins.

V V Bichko1, S M Lemon, J G Wang, S Hwang, M M Lai, J M Taylor.   

Abstract

A total of 17 antibodies, raised in several nonhuman species and specific for different regions on the delta antigen (delta Ag), were used to map, via immunoprecipitation, those domains exposed on the surface of the viral ribonucleoprotein (RNP). These studies showed that the domains for the nuclear localization signal and the C-terminal extension, unique to the large form of delta Ag, are exposed. Also exposed is the C-terminal region of the small form of delta Ag. In contrast, reactivity was not found with the coiled-coil domain needed for protein dimerization. When the hepatitis delta virus (HDV) RNA was released by treatment of viral RNP with vanadyl ribonucleoside complexes, no change in the pattern of delta Ag epitope presentation was detected, consistent with the interpretation that a multimeric protein structure persists in the absence of RNA. These RNP studies have implications not only for understanding of the process of HDV assembly but also for evaluation of the immune responses of an infected host to HDV replication.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8709197      PMCID: PMC190595          DOI: 10.1128/JVI.70.9.5807-5811.1996

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Oligomerization of hepatitis delta antigen is required for both the trans-activating and trans-dominant inhibitory activities of the delta antigen.

Authors:  Y P Xia; M M Lai
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Immunoblot analysis demonstrates that the large and small forms of hepatitis delta virus antigen have different C-terminal amino acid sequences.

Authors:  J G Wang; J Cullen; S M Lemon
Journal:  J Gen Virol       Date:  1992-01       Impact factor: 3.891

3.  The antigen of hepatitis delta virus: examination of in vitro RNA-binding specificity.

Authors:  M Chao; S Y Hsieh; J Taylor
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

4.  Hepatitis delta virus antigen forms dimers and multimeric complexes in vivo.

Authors:  J G Wang; S M Lemon
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

5.  Immunogenic domains of hepatitis delta virus antigen: peptide mapping of epitopes recognized by human and woodchuck antibodies.

Authors:  J G Wang; R W Jansen; E A Brown; S M Lemon
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

6.  A unique conformation at the carboxyl terminus of the small hepatitis delta antigen revealed by a specific monoclonal antibody.

Authors:  S B Hwang; M M Lai
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

7.  Assembly of hepatitis delta virus particles.

Authors:  W S Ryu; M Bayer; J Taylor
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

8.  RNA-binding activity of hepatitis delta antigen involves two arginine-rich motifs and is required for hepatitis delta virus RNA replication.

Authors:  C Z Lee; J H Lin; M Chao; K McKnight; M M Lai
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

9.  Relating structure to function in the hepatitis delta virus antigen.

Authors:  D W Lazinski; J M Taylor
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

10.  Epitopes recognized by antibodies to denatured core protein of hepatitis B virus.

Authors:  V Bichko; F Schödel; M Nassal; E Gren; I Berzinsh; G Borisova; S Miska; D L Peterson; E Gren; P Pushko
Journal:  Mol Immunol       Date:  1993-02       Impact factor: 4.407

View more
  8 in total

1.  Hepatitis delta antigen mediates the nuclear import of hepatitis delta virus RNA.

Authors:  H C Chou; T Y Hsieh; G T Sheu; M M Lai
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

2.  Protein-peptide arrays for detection of specific anti-hepatitis D virus (HDV) genotype 1, 6, and 8 antibodies among HDV-infected patients by surface plasmon resonance imaging.

Authors:  Marie-Bernadette Villiers; Jean-Claude Cortay; Sandra Cortès; Bénédicte Bloquel; Ségolène Brichler; Carine Brakha; Alan Kay; Nisrine Falah; Fabien Zoulim; Christophe Marquette; Patrice N Marche; Paul Dény
Journal:  J Clin Microbiol       Date:  2015-01-28       Impact factor: 5.948

3.  Arginine-rich motifs are not required for hepatitis delta virus RNA binding activity of the hepatitis delta antigen.

Authors:  Leighton H Daigh; Brittany L Griffin; Ali Soroush; Murad R Mamedov; John L Casey
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

4.  Hepatitis Delta Antigen Regulates mRNA and Antigenome RNA Levels during Hepatitis Delta Virus Replication.

Authors:  Kaneemozhe Harichandran; Yiran Shen; Susannah Stephenson Tsoris; See-Chi Lee; John L Casey
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

5.  Multimerization of hepatitis delta antigen is a critical determinant of RNA binding specificity.

Authors:  Brian C Lin; Dawn A Defenbaugh; John L Casey
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

6.  Hepatitis delta antigen requires a flexible quasi-double-stranded RNA structure to bind and condense hepatitis delta virus RNA in a ribonucleoprotein complex.

Authors:  Brittany L Griffin; Sergey Chasovskikh; Anatoly Dritschilo; John L Casey
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

7.  Receptor binding sites and antigenic epitopes on the fiber knob of human adenovirus serotype 3.

Authors:  H Liebermann; R Mentel; U Bauer; P Pring-Akerblom; R Dölling; S Modrow; W Seidel
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

8.  Development and performance of prototype serologic and molecular tests for hepatitis delta infection.

Authors:  Kelly E Coller; Emily K Butler; Ka-Cheung Luk; Mary A Rodgers; Michael Cassidy; Jeffrey Gersch; Anne L McNamara; Mary C Kuhns; George J Dawson; Lazare Kaptue; Birgit Bremer; Heiner Wedemeyer; Gavin A Cloherty
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.